Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis.

摘要: Abstract Autologous hematopoietic stem cell transplantation (ASCT) for multiple myeloma (MM) is associated with high symptom burden, particularly older patients and those amyloid light-chain (AL) amyloidosis. Symptom burden peaks during leukopenia. We hypothesized that higher doses of CD34+ cells would be an improved outcome. Patients undergoing ASCT MM who were ≥60 years old or had AL amyloidosis randomized to receive either a standard (4 6 × 106 cells/kg) dose (10 15 × after melphalan 200 mg/m2. was assessed via the MD Anderson Inventory module. Eighty enrolled. Median 5.1 × cells/kg (standard dose) 10.5 × (high dose). The most severe symptoms first week fatigue, lack appetite, drowsiness, disturbed sleep, pain. area under curve mean composite severity score these similar between treatment arms (P = .819). times neutrophil, lymphocyte, platelet engraftment also groups. IL-6 increased similarly both groups throughout course. Infusion autologous high-dose chemotherapy does not yield difference in time few weeks ASCT.